Ketogan | 100% Good Quality
Ketobemidone, sold under the brand name Ketogan among others, is a powerful synthetic opioid painkiller.
Ketobemidone, sold under the brand name Ketogan among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway and Sweden and is used for severe pain.
Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA.
Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories, and injection fluid. A sustained release formulation exists, sold as Ketodur, in some countries containing 10 or 25 mg ketobemidone.
Experiments on former addicts indicated it was quite addictive and in high doses, compared to other opioids, may have increased abuse potential in former and current opioid addicts. While some effort was first suggested for drafting of a resolution urging governments to stop manufacture and use of ketobemidone. This result was not in agreement with clinical observations, and another study in 1958 did not find it more addictive than morphine. That study noticed that while for morphine the dose for euphoria is the same as that for analgesia, for ketobemidone the analgesic dose was well below the euphoric dose. Thus, even compared to morphine, ketobemidone may be much more effective without causing significant euphoria and this having a lower risk of addiction under the supervision or a qualified clinician.  Ketobemidone is mostly used in the Scandinavian countries, with Denmark topping the statistics.
Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the hydrochloride, which is a white powder. It is synthesized by alkylating (3-methoxyphenyl)acetonitrile with bis(2-chloroethyl)methylamine, followed by reaction with ethylmagnesium bromide, and finally O-demethylation with hydrobromic acid.
Because of a strong vesicant nature of bis(2-chloroethyl)methylamine there are many other routes developed for obtaining ketobemidone. A route depicted below lays through first alkylating the same (3-methoxyphenyl)acetonitrile with 2-chloro-N,N-dimethylethylamine or 2-chloro-N-benzyl-N-methylethylamine. Next, those amines are alkylated once again using a mixed 1-bromo-2-chloroethane, thus completing the piperidine ring and obtaining a quaternary ammonium salt, which can be dequaternized using thiophenol salt (for N,N-dimethylammonium) or catalytic hydrogenation (for both compounds) to a common 4-(3-methoxyphenyl)-4-cyano-1-methyl-pyperidine. The later yields ketobemidone after Grignard reaction with ethylmagnesium bromide and ether cleavage.
- Acetoxymethylketobemidone (O-AMKD)
A survey of 76 cases of fatal intoxication with Ketogan which occurred in Eastern Denmark over the period 1985-1991 showed that the cause of death was Ketogan alone in 27 cases, in combination with alcohol in 23 cases, and in combination with other drugs in 26 cases. The average age, percentage of females, drug addicts and alcohol abusers and the manner of death were also recorded. There was a significant difference between the median values of the blood concentrations of ketobemidone where the blood alcohol concentration (BAC) was zero and where it was greater than 1 mg/g, and also between the median values of the blood concentrations from fatal intoxications and those from living persons.
- PubChem. “Ketobemidone”. https://pubchem.ncbi.nlm.nih.gov/com… (accessed September 17, 2018).
- DrugBank. “Ketobemidone”. http://www.drugbank.ca/drugs/DB06738 (accessed September 17, 2018).
- DTP/NCI. “Ketobemidone: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.”. https://dtp.cancer.gov/dtpstandard/s… (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Ketogan are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ketogan. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.